By Joel Wright, President, Pharmacy Services
Key takeaways
- The Health Resources and Services Administration (HRSA) 340B rebate model pilot begins January 1, 2027, with 10 approved manufacturer plans, all running through the Beacon platform.
- For pilot drugs, covered entities will buy at wholesale acquisition cost (WAC) and receive the 340B savings later as a post-dispense rebate.
- Covered entities have up to 45 calendar days from dispense to submit claim-level data, and manufacturers then have 10 calendar days to pay or deny, which can leave savings outstanding for roughly 50 to 60 days.
- Five steps you can start now without waiting for more guidance: name an owner, size your exposure at WAC, model and fund the cash flow gap, confirm your submission path, and build reconciliation into 340B governance.
What did HRSA announce on October 1, 2026?
The Health Resources and Services Administration (HRSA) has posted 10 approved manufacturer plans and updated FAQs for the pilot, which begins January 1, 2027. Eighteen drugs from 10 manufacturers are in scope, including Eliquisâ„¢, Jardianceâ„¢, Farxigaâ„¢, Januviaâ„¢, Enbrelâ„¢, Imbruvicaâ„¢, Xtandiâ„¢, Ibranceâ„¢, and Trelegy Elliptaâ„¢. All approved plans run through the Beacon platform, and drugs without an approved plan stay on upfront 340B pricing.
For this set of widely dispensed drugs, the 340B benefit moves from upfront to after the fact. That adds new steps for registration, claims submission, reconciliation, and cash flow, and covered entities have about three months to prepare. The five steps below still hold, and they’re easier to act on now. You can run your purchase history against a defined drug list (step 2), and you know which platform your submission path has to work with (step 4).
Our team is working through each approved plan and HRSA’s FAQs, drug by drug and national drug code by NDC, so we can support our partners ahead of January 1.
How does the 340B rebate model pilot work?
The 340B rebate model pilot is a Health Resources and Services Administration (HRSA) program that changes how covered entities receive 340B pricing on selected drugs. Instead of a ceiling-price discount at purchase, the covered entity pays wholesale acquisition cost (WAC), then submits claim-level data to receive the difference as a rebate after dispensing.
The fundamentals of 340B stay in place. The mechanics change. Instead of getting ceiling-price discounts at purchase, covered entities will buy pilot drugs at wholesale acquisition cost (WAC) and receive the savings later as a post-dispense rebate. Wholesaler accounts and ordering channels stay the same, but timelines, data requirements, and cash flow look very different.
Waiting for final guidance is a risk. The organizations best prepared for the pilot, and for the Medicare maximum fair price (MFP) expansion, will have a partner or solution that tracks claims at the claim level, documents why each claim qualifies for a rebate, and lets them act on it quickly. The details may still shift, but the skills the pilot demands (claim-level tracking, documentation, cash flow management, fast reconciliation) can be built today.
Key dates and deadlines for the 340B rebate pilot
- October 1, 2026: HRSA posts 10 approved manufacturer plans and updated FAQs.
- January 1, 2027: Pilot begins for drugs with an approved plan.
- Up to 45 calendar days from dispense: Covered entity submits claim-level data.
- 10 calendar days after submission: Manufacturer pays or denies with a documented rationale.
1. Name an owner and form a cross-functional workgroup
The pilot touches pharmacy, 340B program administration, finance, revenue cycle, IT, and compliance. No single department can manage it alone.
Name one accountable leader and build a workgroup around them with a representative from each function. This team will run the readiness assessment, cash flow modeling, technology decisions, and the change management plan as HRSA updates its guidance.
2. Quantify your exposure
Pull 12 months of purchase history for the drugs affected by the pilot and value it at wholesale acquisition cost (WAC), not the 340B price. WAC is what you’ll pay at purchase once the pilot starts.
Segment the data by dispensing site: retail, specialty, contract pharmacy, and physician-administered workflows. This shows where the pilot will hit hardest and which sites and systems need the most attention.
3. Model and fund the cash flow gap
This is where the rebate model could cause the most disruption. Covered entities have up to 45 calendar days from the date of dispense to submit claim-level data, and manufacturers then have 10 calendar days to pay or deny with a documented rationale. That can leave savings outstanding for roughly 50 to 60 days.
The way to shrink that gap is to submit as soon as possible after dispensing, keep clear documentation of why each claim qualified, and collect quickly. Done well, a 50- to 60-day gap could drop to 12 to 15 days.
Compare the WAC-to-340B spread (wholesale acquisition cost versus 340B ceiling price) against your wholesaler payment terms. If those terms are shorter than the rebate cycle, you have a real cash flow gap, not just a timing difference. Work with finance now to decide how to fund the receivable (reserves, credit lines, or renegotiated wholesaler agreements) and set recognition policies before implementation, not after.
4. Confirm your technology and submission path
Rebate eligibility attaches to the dispense. Submissions require specified pharmacy and medical claims fields, delivered through a manufacturer-funded platform (Beacon, for every plan approved so far). Before the pilot begins, decide whether you’ll submit directly or delegate to a vendor, and which systems and locations that solution must cover.
Either way, document who prepares, transmits, and tracks each claim. Claim-level tracking is the foundation for getting paid and for defending your submissions if they’re questioned.
5. Build reconciliation and reporting into 340B governance
Treat rebate operations as part of 340B governance and financial oversight, not a side process. Assign clear ownership for reconciliation to pharmacy, finance, revenue integrity, or 340B staff, and make sure they have systems that match every rebate payment to the dispense that generated it, at the unit level.
Track expected rebates, payments received, payment timing, denials, appeals, and outstanding balances in centralized dashboards, with views by entity, pharmacy, and drug. Treat expected-versus-actual variance as a key financial control. It lets teams catch short payments, flag rebates that have aged past required timeframes, investigate discrepancies, and manage appeals.
Organizations with audit-ready reconciliation can answer three questions quickly: what they’re owed, what they’ve received, and what’s still under review.
Next steps
Name an owner, size your exposure at WAC, model the cash flow gap, settle your submission path, and build reconciliation into your governance. None of that depends on further HRSA guidance, and with about three months until January 1, the work is better started now than squeezed in later.
Contact us to discuss what this means for your 340B program.
Frequently asked questions about the 340B rebate pilot
When does the 340B rebate pilot start?
The Health Resources and Services Administration (HRSA) 340B rebate model pilot begins January 1, 2027. HRSA posted 10 approved manufacturer plans and updated FAQs for the pilot on October 1, 2026.
Which drugs are included in the 340B rebate pilot?
Eighteen drugs from 10 manufacturers are in scope, including Eliquis, Jardiance, Farxiga, Januvia, Enbrel, Imbruvica, Xtandi, Ibrance, and Trelegy Ellipta. Drugs without an approved manufacturer plan stay on upfront 340B pricing.
What platform is used to submit 340B rebate pilot claims?
All approved manufacturer plans run through the Beacon platform, which is manufacturer-funded. Covered entities can submit claim-level data directly or delegate submission to a vendor.
How long do covered entities have to submit 340B rebate claims?
Covered entities have up to 45 calendar days from the date of dispense to submit claim-level data. Manufacturers then have 10 calendar days to pay or deny the rebate with a documented rationale.
Do covered entities need new wholesaler accounts for the 340B rebate pilot?
No. Wholesaler accounts and ordering channels stay the same. What changes is the price at purchase: pilot drugs are bought at wholesale acquisition cost (WAC), and the 340B savings arrive later as a post-dispense rebate.
How can a covered entity shorten the 340B rebate cash flow gap?
Submit claims as soon as possible after dispensing, keep clear documentation of why each claim qualified, and collect quickly. Done well, a 50- to 60-day gap could drop to 12 to 15 days.
Joel Wright is a registered pharmacist and the President of Pharmacy Services at VytlOne. He has over 30 years of healthcare experience across retail operations, specialty pharmacy, managed pharmacy, health system and center pharmacy operations, and home infusion. Joel is dedicated to patient care, improving patient outcomes, and optimizing healthcare processes through innovation.